QuorumCivic. Hidden in plain sight Get the app
Bill intelligence

Federal program funds addiction treatment hubs in high-overdose communities

S. 665 — Fatal Overdose Reduction Act of 2025 · Filed by Maria Cantwell (D-WA) · 1 cosponsor · Introduced Feb 20, 2025 · Referred to committee

72%
Transparency
Typical bill: 82%
15/100
Hidden-provision risk
Typical bill: 15/100
Public Health Demonstration Program

Your members of Congress

Enter a ZIP to see where your representative and both senators stood on this bill.

Looked up on this device — your ZIP is never stored on our servers.

What it does

This bill creates a five-year federal demonstration program under Medicaid to fund 'Health Engagement Hubs'—drop-in centers in high-overdose communities that provide opioid and substance use disorder treatment, harm reduction supplies, mental health services, and wraparound social services (housing help, legal aid, employment counseling). States apply to participate; the federal government covers 90% of costs through a prospective payment system. The bill appropriates $60 million for planning grants, administration, and evaluation.

Why we flagged it

The bill's operative mechanism is a federal-state partnership to establish and fund community-based addiction treatment and harm reduction centers. It is a public health infrastructure investment, not a regulatory change, tax provision, or private subsidy.

What the text implies

  • The bill requires at least 50% of hubs in high-overdose counties or mental health shortage areas, but does not mandate rural coverage—rural areas may be underserved if they fall outside these criteria, potentially widening geographic disparities in access.
  • The prospective payment system is state-designed and state-administered; variation across states may create inconsistent service quality, reimbursement rates, and eligibility standards, making outcomes difficult to compare and potentially disadvantaging residents of lower-resourced states.

The full analysis lists 5 implications of this text.

Who stands to gain

Federally qualified health centers and community health centers (as partner organizations); Substance use disorder treatment providers and clinics (as partner organizations); Pharmaceutical manufacturers of opioid use disorder medications (buprenorphine, methadone, naltrexon

Correlative observation from public records — not evidence of coordination or wrongdoing, and not financial advice.
This page is the record as of today. The app tells you when it changes.
Quorum analysis of the full bill text · 119th Congress · public record